Table 2.
Associations of BIA-BF%-equations, body mass index and waist circumference with cardiovascular events in men.
| Obesity measures | Hazard ratio (95% CI) |
||
|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |
| Body mass index | 1.26 (1.12–1.42)**** | 1.24 (1.10–1.40)** | 1.28 (1.12–1.47)**** |
| Waist circumference | 1.30 (1.15–1.47)**** | 1.27 (1.12–1.44)**** | 1.32 (1.15–1.51)**** |
| Body fat percentage | |||
| BIA 101 AKERN | 1.23 (1.04–1.45)* | 1.22 (1.03–1.44)* | 1.23 (1.03–1.46)* |
| Heitmann1 | 1.76 (1.29–2.39)**** | 1.67 (1.22–2.28)** | 1.77 (1.27–2.46)*** |
| Heitmann2 | 1.41 (1.17–1.70)**** | 1.37 (1.13–1.65)** | 1.41 (1.16–1.73)** |
| Segal1 | 1.32 (1.15–1.53)**** | 1.29 (1.12–1.49)** | 1.34 (1.14–1.56)*** |
| Segal2 | 1.36 (1.15–1.61)**** | 1.32 (1.12–1.56)** | 1.35 (1.13–1.60)** |
| Segal3 | 1.68 (1.25–2.24)*** | 1.59 (1.19–2.14)** | 1.58 (1.18–2.13)** |
| Segal4 | 1.45 (1.19–1.76)**** | 1.40 (1.15–1.71)** | 1.41 (1.15–1.73)** |
| Segal5 | 1.29 (1.12–1.49)**** | 1.26 (1.10–1.45)** | 1.31 (1.12–1.53)** |
| Segal6 | 1.36 (1.17–1.58)**** | 1.32 (1.14–1.54)**** | 1.37 (1.16–1.62)**** |
| Van-Loan-Mayclin | 1.60 (1.27–2.02)**** | 1.53 (1.21–1.94)**** | 1.59 (1.24–2.05)**** |
| Kyle | 1.28 (1.10–1.50)*** | 1.26 (1.08–1.46)** | 1.28 (1.09–1.51)** |
| Aglago1 | 1.27 (1.06–1.53)* | 1.24 (1.03–1.49)* | 1.27 (1.04–1.54)* |
| Deurenberg | 1.40 (1.15–1.69)**** | 1.35 (1.11–1.64)** | 1.37 (1.12–1.68)** |
| Boulier | 1.22 (0.98–1.53) | ||
| Chumlea | 1.26 (1.06–1.49)*** | 1.23 (1.04–1.46)* | 1.23 (1.03–1.47)* |
| Gray1 | 1.37 (1.17–1.60)**** | 1.33 (1.14–1.55)**** | 1.36 (1.16–1.61)**** |
| Gray2 | 1.24 (1.06–1.45)** | 1.21 (1.03–1.42)* | 1.21 (1.03–1.42)* |
| Jebb | 1.18 (1.04–1.3)* | 1.16 (1.02–1.31)* | 1.18 (1.03–1.35)* |
| Lukaski1 | 1.17 (1.03–1.34)* | 1.15 (1.01–1.31)* | 1.15 (1.01–1.32)* |
| Lukaski2 | 1.17 (1.03–1.34)* | 1.15 (1.01–1.31)* | 1.15 (1.01–1.32)* |
| Lukaski3 | 1.22 (1.07–1.40)** | 1.20 (1.04–1.37)* | 1.20 (1.05–1.38)* |
| Rising | 1.31 (1.07–1.61)* | 1.27 (1.03–1.56)* | 1.29 (1.04–1.60)* |
| Stolarczyk | 1.37 (1.18–1.59)**** | 1.34 (1.15–1.55)**** | 1.37 (1.18–1.61)**** |
| Wattanapenpaiboon1 | 1.17 (1.03–1.33)* | 1.16 (1.02–1.32)* | 1.16 (1.02–1.32)* |
| Wattanapenpaiboon2 | 1.17 (1.03–1.33)* | 1.15 (1.01–1.31)* | 1.16 (1.01–1.32)* |
| Sun | 1.22 (1.03–1.45)* | 1.19 (1.01–1.42)* | 1.19 (1.00–1.42)* |
| Aglago2 | 1.27 (1.06–1.52)* | 1.24 (1.03–1.49)* | 1.26 (1.04–1.53)* |
| Heitmann3 | 1.26 (1.11–1.42)**** | 1.23 (1.09–1.40)** | 1.25 (1.09–1.42)** |
| Kushner | 1.18 (1.02–1.34)* | 1.15 (1.00–1.32)* | 1.15 (1.00–1.32)* |
| Kushner_Schoeller1 | 1.17 (1.02–1.34)* | 1.15 (1.00–1.31)* | 1.15 (1.00–1.32)* |
| Kushner_Schoeller2 | 1.18 (1.04–1.33)* | 1.16 (1.02–1.31)* | 1.17 (1.02–1.33)* |
| Kushner_Schoeller3 | 1.17 (1.04–1.33)* | 1.16 (1.02–1.31)* | 1.17 (1.02–1.33)* |
| Lukaski_Bolunchuk1 | 1.24 (1.04–1.47)* | 1.21 (1.02–1.44)* | 1.22 (1.02–1.45)* |
| Lukaski_Bolunchuk2 | 1.24 (1.04–1.49)* | 1.21 (1.01–1.45)* | 1.22 (1.02–1.46)* |
Model1: adjusted for age; Model2: adjusted for age, Framingham CVD risk score; Model3: adjusted for age, Framingham CVD risk score, creatinine excretion – a marker of muscle mass.
Data are presented if the measures remained significant after further adjustments.
*
p < 0.05
**
p < 0.01
***
p < 0.001
****
p < 0.0001
BIA: bioelectrical impedance analysis; BF%: body fat percentage; CI: confidence interval; CVD: cardiovascular disease